This trial hopes to find out if a new treatment is safe and effective in treating prostate cancer that can't be treated with another method.
- Castration-resistant Prostate Cancer
- Prostate Cancer
Phase 1 & 2
12 Primary · 0 Secondary · Reporting Duration: Up to 5 years
Up to 12 months
Incidence of 64Cu-SAR-BBN treatment-emergent adverse events [Safety and tolerability]
Incidence of 67Cu-SAR-BBN treatment-emergent adverse events [Safety and tolerability]
Up to 14 weeks
Incidence of dose limiting toxicities [Safety and tolerability] of 67Cu-SAR-BBN
Recommended dose of two doses of 67Cu-SAR-BBN
Safety and tolerability of 67Cu-SAR-BBN
Up to 24 weeks
Safety and tolerability of 67Cu-SAR-BBN: Number of Participants with changes from baseline in electrocardiogram (ECG) parameters
Safety and tolerability of 67Cu-SAR-BBN: Number of Participants with changes from baseline in vital signs
Up to 5 years
Efficacy of 67Cu-SAR-BBN in terms of Prostate Specific Antigen (PSA) response
Efficacy of 67Cu-SAR-BBN in terms of radiographic response
Incidence of 67Cu-SAR-BBN adverse event of special interest [Safety and tolerability]
Up to 52 weeks
Safety and tolerability of 67Cu-SAR-BBN: Number of Participants with changes from baseline in laboratory results
Up to 8 weeks
Maximum tolerated dose (MTD) or maximum feasible dose (MFD) of a single dose of 67Cu-SAR-BBN
Awards & Highlights
No Placebo Group
All patients enrolled in this trial will receive the new treatment.
1 Treatment Group
1 of 1
38 Total Participants · 1 Treatment Group
Primary Treatment: 67Cu-SAR-BBN · No Placebo Group · Phase 1 & 2
67Cu-SAR-BBNExperimental Group · 2 Interventions: 67Cu-SAR-BBN, 64Cu-SAR-BBN · Intervention Types: Drug, Drug
Screening: ~3 weeks
Reporting: up to 5 years
Who is running the clinical trial?
Clarity Pharmaceuticals LtdLead Sponsor
9 Previous Clinical Trials
317 Total Patients Enrolled
1 Trials studying Prostate Cancer
30 Patients Enrolled for Prostate Cancer
Age 18+ · Male Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
You are expected to live for at least 6 more months.
- 2023. "64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05633160.
Frequently Asked Questions
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available vacancies for this research project?
"As of the most recent update on April 11th, 2023; this clinical trial is not presently accepting any patients. Despite that, there are 1249 other trials actively recruiting across a variety of conditions and treatments." - Anonymous Online Contributor